<DOC>
	<DOCNO>NCT01094067</DOCNO>
	<brief_summary>Multicenter , double-blind , randomize , placebo-controlled , cross-over study demonstrate single infusion tezosentan minimal effect blood pressure patient pulmonary arterial hypertension , treat endothelin receptor antagonist , phosphodiesterase-5 inhibitor combination .</brief_summary>
	<brief_title>Tezosentan Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Inclusion Criteria : 1 . Signed informed consent prior initiation studymandated procedure 2 . Male female patient 18 year age old 3 . Patients PAH accord one follow subgroup Dana Point Classification Group 1 : Idiopathic , Heritable , Associated connective tissue disease 4 . Documented hemodynamic diagnosis PAH right heart catheterization ( part study mandate procedure ) : Resting mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg Resting mean pulmonary vascular resistance ( PVR ) ≥ 240 dyn•s•cm 5 Pulmonary capillary wedge pressure ≤ 15 mmHg 5 . Modified NYHA functional class IIIII 6 . Patients treatment ERAs , PDE5 inhibitor combination , use least 3 month prior Visit 1 dose keep stable least 28 day prior Visit 1 . Exclusion Criteria : 1 . Patients PAH Dana Point Classification Groups 25 , PAH Group 1 subgroup cover inclusion criterion No . 3 2 . Patients sit SBP &lt; 100 mmHg 3 . Patients sit DBP &lt; 60 mmHg 4 . Patients body weight &lt; 50 kg ( 110 lb ) 5 . Patients clinically significantly elevate liver enzyme ( AST , ALT and/or alkaline phosphatase &gt; 3 time upper limit ) 6 . Patients clinically significant chronic renal insufficiency ( serum creatinine &gt; 2.5mg/dL / 221 µmol/L ) 7 . Patients moderate severe hepatic impairment ( ChildPugh B C ) 8 . Patients receive prostacyclin ( epoprostenol ) prostacyclin analog ( e.g. , treprostinil , iloprost beraprost ) within 28 day Visit 1 9 . Patients receive investigational drug within 28 day Visit 1 10 . Patients receive cyclosporine A ( CsA ) tacrolimus within 28 day Visit 1 11 . Psychotic , addictive disorder limit ability provide inform consent comply study 12 . Life expectancy le 12 month 13 . Females lactate pregnant ( positive pretreatment pregnancy test ) ( serum test Screening urine test Visit 1 2 ) female use reliable method birth control ( failure rate le 1 % per year ) study least one month last administration study drug 14 . Known hypersensitivity excipients drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>